This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Lowe, G. Search for Related Content Social Bookmarking                         What's this?

Review: Which patients with diabetes should receive which antiplatelet agents?

University Department of Medicine, Royal Infirmary, Glasgow, G31 2ER, UK, gdl1j{at}clinmed.gla.ac.uk

Patients with diabetes mellitus tend to have activated blood platelets, and increased circulating levels of co-factors (fibrinogen, von Willebrand factor) which promote platelet adhesion, aggregation and thrombosis. Systematic reviews of randomised controlled trials of antiplatelet agents show that antiplatelet agents reduce the risk of serious vascular events (myocardial infarction, stroke or death) by about one-quarter in patients with symptomatic vascular disease (secondary prevention), including those with diabetes. So, secondary prevention with an antiplatelet agent (aspirin, clopidogrel, or dipyridamole) should be considered in all diabetic patients with symptomatic vascular disease. Systematic reviews of randomised controlled trials of aspirin in primary prevention show a similar proportional reduction in coronary heart disease events, but not in stroke or death. The excess of adverse events for aspirin (haemorrhagic stroke, major gastrointestinal bleeds), which is unrelated to risk of cardiovascular disease, results in a lower risk: benefit ratio in primary prevention, and is also less cost-effective when aspirin is prescribed. Current SIGN guidelines recommend that aspirin be considered for primary prevention of coronary heart disease in diabetic or non-diabetic persons whose coronary risk is formally estimated to be 2% per year (in practice, over 80% of diabetic adults without symptomatic vascular disease). Discussions between clinicians and patients should address the potential benefits and harms of aspirin in primary prevention, as well as patient preferences. Further trials are required to identify subgroups in whom primary prevention is most beneficial.

Key Words: diabetes • platelets • coronary heart disease • aspirin.

References

• Mills JD, Grant PJ Insulin resistance, haemostatic factors and cardiovascular risk. Br J Diabetes Vasc Dis 2002;2:19-26.[Abstract/Free Full Text]
• Grant PJ Risk factors for arterial disease in diabetes: coagulopathy. In: Tooke JE (ed.). Diabetic Angiopathy. London: Arnold, 1999:93-11.
• Winocour PD Platelet abnormalities in diabetes mellitus. Diabetes 1992; 41:26-31.[Abstract]
• Danesh J., Whincup PH, Walker M. et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000;321:199-204.[Abstract/Free Full Text]
• Whincup P., Danesh J., Walker M. et al. Von Willebrand factor and coronary heart disease: new prospective study and meta-analysis. Euro Heart J 2002;in press.
• Dent MT, Preston FE, Ward JD Elevated von Willebrand factor antigen predicts deterioration in diabetic peripheral nerve function. Diabetologia 1996;39:336-43.[Web of Science][Medline] [Order article via Infotrieve]
• Antithrombotic Trialists' Collaboration. Collaborative meta-analyses of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324: 71-86.[Abstract/Free Full Text]
• US Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002;136:157-60.[Abstract/Free Full Text]
• Hankey G., Sudlow C., Dunbabin DW Thienopyridines versus aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomised trials. Stroke 2000;31:1779-84.[Abstract/Free Full Text]
• Woodward M., Lowe GDO, Francis LM, Rumley A., Cobbe S. A randomised comparison of the effects of clopidogrel and aspirin on thrombotic variables and C-reactive protein following myocardial infarction. J Am Coll Card 2002;39:(suppl A): Abstract 1027-38.
• Eikelboom JW, Weitz JI, Johnston M., Yi Q., Yusof S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke or cardiovascular death in patients at high risk of cardiovascular events. Circulation 2002;105:1650-5.[Abstract/Free Full Text]
• Chew EY, Klein ML, Murphy RP, Rewaley NA, Ferris FL Early treatment Diabetic Retinopathy Study Research Group. Effects of aspirin on vitreous/preretinal haemorrhage in patients with diabetes mellitus. Arch Ophthalmol 1995;113:52-5.[Abstract/Free Full Text]
• Scottish Intercollegiate Guidelines Network (SIGN). Antithrombotic therapy (SIGN Guideline 36). Edinburgh: SIGN 1999 (available on www.sign. ac.uk).
• Scottish Intercollegiate Guidelines Network (SIGN). Management of diabetes (SIGN Guideline 55). Edinburgh: SIGN 2001 (available on www. sign.ac.uk).
• Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial investigators. Effect of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.[Abstract/Free Full Text]
• Mehta SR, Yusuf S., Peters RJG et al., for the Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• British National Formulary No 43, March 2002.
• Sanmugathan PS, Ghahramani P., Jackson PR, Wallis EJ, Ramsay LE Aspirin for primary prevention of coronary disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001;85:265-71.[Abstract/Free Full Text]
• McMahon AD, MacDonald TM, Davey PG, Cleland JGF. The impact of low-dose aspirin prescribing on upper gastrointestinal toxicity, renal toxicity and healthcare resource utilisation. Edinburgh: Chief Scientist Office, 2001:1.
• Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998;80(suppl 2):S1.[Free Full Text]

The British Journal of Diabetes & Vascular Disease, Vol. 2, No. 3, 157-160 (2002)
DOI: 10.1177/14746514020020030201


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Kennedy Comparing audits of cardiovascular risk in patients with diabetes in primary care The British Journal of Diabetes & Vascular Disease, July 1, 2003; 3(4): 295 - 299. [Abstract] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Lowe, G. Search for Related Content Social Bookmarking                         What's this?